Evidence map›Paper›PMID 23206440›Full record

Trial reportTrials2012

Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial.

Lun-Chien Lo, Chia-Yun Chen, Shou-Tung Chen, Hung-Chang Chen, Tsung-Chieh Lee, Cheng-Shyong Chang

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01580358 (Changhua Christian Hospital), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01580358 naunknown statusnot on this map

Changhua Christian Hospital

TypeinterventionalSponsorChanghua Christian HospitalRan2009 to 2012Enrolled60ConditionsCancer Patients Undergoing Chemotherapy or RadiotherapyArmsShen-Mai San, Starch
3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Ren Shen Yangrong Tang for Fatigue in Cancer Survivors: A Phase I/II Open-Label Study.Journal of alternative and complementary medicine (New York, N.Y.) · 2015
    Trial
  3. Article
  4. Article
  5. Review
  6. Pharmacokinetic Herb-Drug Interactions ofFrontiers in pharmacology · 2022
    Article
  7. Review
  8. Protein Hydrolyzates from Changbai Mountain Walnut (Evidence-based complementary and alternative medicine : eCAM · 2018
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Ginseng and anticancer drug combination to improve cancer chemotherapy: a critical review.Evidence-based complementary and alternative medicine : eCAM · 2014
    Review
  15. Investigation into the influence of physician for treatment based on syndrome differentiation.Evidence-based complementary and alternative medicine : eCAM · 2013
    Article
  16. Protective effect of curcumin on chemotherapy-induced intestinal dysfunction.International journal of clinical and experimental pathology · 2013
    Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lun-Chien LoDepartment of Chinese Medicine, Changhua Christian Hospital, 135 NanxiaoSt, Changhua City, Changhua Country 500, Taiwan.
Chia-Yun Chen
Shou-Tung Chen
Hung-Chang Chen
Tsung-Chieh Lee
Cheng-Shyong Chang

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer is one of the major health issues worldwide. An increasing number of cancer patients are offered treatment with surgery, chemotherapy and radiotherapy. Traditional Chinese medicine (TCM) is one of the most common complementary therapies offered to cancer patients in Taiwan. We designed a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of TCM in patients with cancer. METHODS/

designIn this study, inclusion criteria are postoperative patients with histologically confirmed cancer within 3 years who are undergoing chemotherapy or radiotherapy, more than 18 years old, have given signed informed consent, have the ability to read Chinese, and the ability for oral intake.Exclusion criteria include being pregnant, breast feeding, having completed chemotherapy or radiotherapy, brain metastasis with Eastern Cooperative Oncology Group (ECOG) performance status of two to four, delusion or hallucinations, acute infection, and have received medications under other clinical trials.The patients were separated into an intervention group (Shen-Mai-San, SMS) and a placebo group for four weeks using a randomized, double-blind procedure. The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QOL-C30) was used to evaluate the quality of life. General data, hemoglobin (Hb), hematocrit (Hct), glutamic-oxalacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), blood urea nitrogen (BUN), creatinine, carcinoembryonic antigen (CEA), TCM diagnosis data and heart rate variability (HRV) were also recorded. These data were collected at baseline, two weeks and four weeks after receiving medication. The patients were prescribed granules which contained therapeutic medicines or placebo. Paired-T test was used for statistical analysis. DISCUSSION: Shen-Mai-San is composed of processed Ginseng radis, Liriope spicata, and Schizandrae fructus. It was found to be effective for treating cancer-related fatigue and had anti-fatigue activity. In TCM theory, SMS has a synergistic effect for qi and yin deficiency and has the ability to prevent fatigue. The symptoms of qi and yin deficiency are similar to chemotherapy- or radiotherapy-induced side effects. In order to evaluate the efficacy of SMS on cancer treatment, we designed a randomized, double-blind, placebo-controlled trial.

trial registrationThis study is registered to Clinical Trails.gov NCT01580358.

Indexed as

Research DesignAntineoplastic Agents, PhytogenicChemotherapy, AdjuvantClinical ProtocolsDouble-Blind MethodDrug CombinationsDrugs, Chinese HerbalFatigueHumansNeoplasmsQiQuality of LifeRadiotherapy, AdjuvantTaiwanTime FactorsTreatment OutcomeAntineoplastic Agents, PhytogenicDrug CombinationsDrugs, Chinese Herbalfructus schizandrae, radix ginseng, radix ophiopogonis drug combination

Identifiers

PMID23206440
PMCPMC3543266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.